| Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population Ü Yasar, E Eliasson, ML Dahl, I Johansson, M Ingelman-Sundberg, ... Biochemical and biophysical research communications 254 (3), 628-631, 1999 | 357 | 1999 |
| Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population MG Scordo, E Aklillu, U Yasar, ML Dahl, E Spina, M Ingelman‐Sundberg British journal of clinical pharmacology 52 (4), 447-450, 2001 | 306 | 2001 |
| Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype Ü Yasar, C Forslund‐Bergengren, G Tybring, P Dorado, A LLerena, ... Clinical Pharmacology & Therapeutics 71 (1), 89-98, 2002 | 282 | 2002 |
| Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation HJ Xie, Ü Yasar, S Lundgren, L Griskevicius, Y Terelius, M Hassan, ... The pharmacogenomics journal 3 (1), 53-61, 2003 | 271 | 2003 |
| Role of CYP2C9 polymorphism in losartan oxidation Ü Yasar, G Tybring, M Hidestrand, M Oscarson, M Ingelman-Sundberg, ... Drug metabolism and disposition 29 (7), 1051-1056, 2001 | 223 | 2001 |
| Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms U Yasar, S Lundgren, E Eliasson, A Bennet, B Wiman, U De Faire, ... Biochemical and biophysical research communications 299 (1), 25-28, 2002 | 176 | 2002 |
| The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro Ü Yasar, E Eliasson, C Forslund-Bergengren, G Tybring, M Gadd, ... European journal of clinical pharmacology 57, 729-735, 2001 | 155 | 2001 |
| Pharmacogenetics of cyclophosphamide in patients with hematological malignancies H Xie, L Griskevicius, L Ståhle, Z Hassan, Ü Yasar, A Rane, U Broberg, ... European journal of pharmaceutical sciences 27 (1), 54-61, 2006 | 140 | 2006 |
| Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction Ü Yasar, AM Bennet, E Eliasson, S Lundgren, B Wiman, U De Faire, ... Pharmacogenetics and Genomics 13 (12), 715-720, 2003 | 137 | 2003 |
| Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase M Sandberg, Ü Yasar, P Strömberg, JO Höög, E Eliasson British journal of clinical pharmacology 54 (4), 423-429, 2002 | 136 | 2002 |
| CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers P Dorado, R Berecz, MJ Norberto, Ü Yasar, ML Dahl, A LLerena European journal of clinical pharmacology 59, 221-225, 2003 | 131 | 2003 |
| Functional impact of CϒP2C9*5, CϒP2C9*6, CϒP2C9*8, and CϒP2C9*11 in vivo among black Africans AC Allabi, JL Gala, Y Horsmans, MO Babaoglu, A Bozkurt, ... Clinical Pharmacology & Therapeutics 76 (2), 113-118, 2004 | 127 | 2004 |
| Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes L Griskevicius, Ü Yasar, M Sandberg, M Hidestrand, E Eliasson, ... European journal of clinical pharmacology 59, 103-109, 2003 | 100 | 2003 |
| CYP2C9 genetic variants and losartan oxidation in a Turkish population MO Babaoglu, U Yasar, M Sandberg, E Eliasson, ML Dahl, SO Kayaalp, ... European journal of clinical pharmacology 60, 337-342, 2004 | 95 | 2004 |
| Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. A Tufan, MO Babaoglu, A Akdogan, U Yasar, M Calguneri, U Kalyoncu, ... The Journal of rheumatology 34 (7), 1540-1544, 2007 | 93 | 2007 |
| Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations Ü Yasar, E Aklillu, R Canaparo, M Sandberg, J Sayi, HK Roh, ... European journal of clinical pharmacology 58, 555-558, 2002 | 78 | 2002 |
| Molecular diagnosis and clinical characterization of pseudohypoparathyroidism type-Ib in a patient with mild Albright’s hereditary osteodystrophy-like features, epileptic … U Unluturk, A Harmanci, M Bayraktar, M Babaoglu, U Yasar, K Varli, ... The American journal of the medical sciences 336 (1), 84-90, 2008 | 73 | 2008 |
| A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes K Laine, Ü Yasar, J Widén, G Tybring Pharmacology & toxicology 93 (2), 77-81, 2003 | 67 | 2003 |
| Inhibitory effect of 5‐fluorouracil on cytochrome P450 2C9 activity in cancer patients A Gunes, U Coskun, C Boruban, N Gunel, MO Babaoglu, O Sencan, ... Basic & clinical pharmacology & toxicology 98 (2), 197-200, 2006 | 61 | 2006 |
| Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood E Gumus, O Karaca, MO Babaoglu, G Baysoy, N Balamtekin, H Demir, ... European journal of clinical pharmacology 68, 629-636, 2012 | 59 | 2012 |
